{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:07Z","timestamp":1793056387085,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.cytogfr.2025.12.004","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:22:52Z","timestamp":1765063372000},"page":"54-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Role of anti-tumorigenic cytokines in gastrointestinal cancers"],"prefix":"10.1016","volume":"87","author":[{"given":"Olivia","family":"Hooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily T.","family":"Childers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Childers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colton C.","family":"Mowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-0409","authenticated-orcid":false,"given":"Sarfraz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/gutjnl-2024-333227","article-title":"Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021","volume":"74","author":"Danpanichkul","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12889-024-21192-3","article-title":"Epidemiological trends in gastrointestinal cancers and risk factors across U.S. states from 2000 to 2021: a systematic analysis for the global burden of disease study 2021","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global Burden of 5 Major Types of Gastrointestinal Cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.12.004_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2019.07.055","article-title":"Epidemiology and Mechanisms of the Increasing Incidence of Colon and Rectal Cancers in Young Adults","volume":"158","author":"Stoffel","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib6","unstructured":"Cancer Facts & Figures 2025, 2025. 2025)."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.12.004_bib7","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.14309\/ajg.0000000000003198","article-title":"Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States","volume":"120","author":"Huang","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph20043640","article-title":"The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?","volume":"20","author":"Jardim","year":"2023","journal-title":"Int J. Environ. Res Public Health"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020167","article-title":"IL-12 Family Cytokines in Cancer and Immunotherapy","volume":"13","author":"Mirlekar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010124","article-title":"Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer","volume":"23","author":"Czajka-Francuz","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.cytogfr.2025.12.004_bib11","first-page":"1563","article-title":"Immunology of IL-12: An update on functional activities and implications for disease","volume":"19","author":"Ullrich","year":"2020","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1590\/s0004-2803.201800000-83","article-title":"Serum Cytokine of Il-2, Il-10 and Il-12 Levels in Patients with Stomach Adenocarcinoma","volume":"55","author":"Shokrzadeh","year":"2018","journal-title":"Arq. Gastroenterol."},{"issue":"1C","key":"10.1016\/j.cytogfr.2025.12.004_bib13","first-page":"635","article-title":"Serum levels of interleukin-12 in patients with gastrointestinal cancer","volume":"20","author":"Nakayama","year":"2000","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib14","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s12029-024-01063-1","article-title":"Expression of Interleukin-8, Interleukin-12 and Interleukin-13 in Esophageal Squamous Cell Carcinoma: Biomarker Potentiality and Prognostic Significance","volume":"55","author":"Talukdar","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib15","article-title":"Interleukin-12 treatment reduces tumor growth and modulates the expression of CASKA and MIR-203 in athymic mice bearing tumors induced by the HGC-27 gastric cancer cell line","volume":"263","author":"Dellalibera-Joviliano","year":"2024","journal-title":"Pathol. Res Pr."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.12.004_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2007.07.025","article-title":"Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer","volume":"47","author":"Zabala","year":"2007","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1006\/mthe.2002.0570","article-title":"Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model","volume":"5","author":"Putzer","year":"2002","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.12.004_bib18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00262-017-2000-4","article-title":"Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow \"in situ tumor vaccination\"?","volume":"66","author":"Deplanque","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.micinf.2011.10.006","article-title":"The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use","volume":"14","author":"Perera","year":"2012","journal-title":"Microbes Infect."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.12.004_bib20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jhep.2014.07.004","article-title":"Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses","volume":"61","author":"Cheng","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000599","article-title":"Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10","volume":"8","author":"Bergamaschi","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0016-5085(03)01047-3","article-title":"Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease","volume":"125","author":"Mention","year":"2003","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.cytogfr.2013.05.004","article-title":"The role of IL-15 in gastrointestinal diseases: A bridge between innate and adaptive immune response","volume":"24","author":"Pagliari","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.12.004_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1002721","article-title":"IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity","volume":"4","author":"Bahri","year":"2015","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.12.004_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.cytogfr.2025.12.004_bib27","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1073\/pnas.1301022110","article-title":"IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.12.004_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1165","article-title":"Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment","volume":"9","author":"Van Audenaerde","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"16_","key":"10.1016\/j.cytogfr.2025.12.004_bib29","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1200\/JCO.2022.40.16_suppl.4147","article-title":"Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti\u2013PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer","volume":"40","author":"Seery","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.12.004_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: Biology, Design and Application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cytogfr.2025.12.004_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433989","article-title":"IL-2 based cancer immunotherapies: an evolving paradigm","volume":"15","author":"Rokade","year":"2024","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/1744666X.2017.1245146","article-title":"Therapy implications of the role of interleukin-2 in cancer","volume":"13","author":"Lissoni","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/07357909109018951","article-title":"The immunotherapy of human cancer with interleukin 2: present status and future directions","volume":"9","author":"Kolitz","year":"1991","journal-title":"Cancer Invest"},{"issue":"17-18","key":"10.1016\/j.cytogfr.2025.12.004_bib35","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1089\/hum.2023.099","article-title":"Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy","volume":"34","author":"Wang","year":"2023","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.12.004_bib37","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","article-title":"JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance","volume":"42","author":"Sabaawy","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The relation between PI3K\/AKT signalling pathway and cancer","volume":"698","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.12.004_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100218","article-title":"Prognostic Value of T-Cell Density in the Tumor Center and Outer Margins in Gastric Cancer","volume":"36","author":"Soeratram","year":"2023","journal-title":"Mod. Pathol."},{"issue":"32","key":"10.1016\/j.cytogfr.2025.12.004_bib40","article-title":"Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis","volume":"97","author":"Lee","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"13","key":"10.1016\/j.cytogfr.2025.12.004_bib41","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.7150\/ijbs.46651","article-title":"The Role of Interleukins in Colorectal Cancer","volume":"16","author":"Li","year":"2020","journal-title":"Int J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s101470200046","article-title":"Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R\/Tac antigen in colorectal cancer","volume":"7","author":"Sakata","year":"2002","journal-title":"Int J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.12.004_bib43","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/bjc.1998.302","article-title":"Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer","volume":"77","author":"Nakata","year":"1998","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib45","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1245\/s10434-006-9239-x","article-title":"Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis","volume":"14","author":"Cesana","year":"2007","journal-title":"Ann. Surg. Oncol."},{"issue":"35","key":"10.1016\/j.cytogfr.2025.12.004_bib46","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.3748\/wjg.v11.i35.5525","article-title":"W. Den Otter, Locoregional IL-2 low dose applications for gastrointestinal tumors","volume":"11","author":"Krastev","year":"2005","journal-title":"World J. Gastroenterol."},{"issue":"1B","key":"10.1016\/j.cytogfr.2025.12.004_bib47","first-page":"599","article-title":"Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C","volume":"26","author":"Brivio","year":"2006","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib48","first-page":"989","article-title":"Modulation of systemic and intestinal immune response by interleukin-2 therapy in gastrointestinal surgical oncology. Personal experience in the context of current knowledge and future perspectives","volume":"32","author":"Nespoli","year":"2012","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-016-0279-7","article-title":"A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment","volume":"23","author":"Liu","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.12.004_bib50","first-page":"2359","article-title":"Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study","volume":"5","author":"Sobol","year":"1999","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib51","first-page":"3445350","article-title":"IL-2 Modulates TAMs Derived Exosomal MiRNAs to Ameliorate Hepatocellular Carcinoma Development and Progression","volume":"2022","author":"Chen","year":"2022","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib52","first-page":"300","article-title":"Genetically engineered recombinant adenovirus expressing interleukin\u20112 for hepatocellular carcinoma therapy","volume":"17","author":"Sun","year":"2018","journal-title":"Mol. Med Rep."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.12.004_bib53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00262-025-04072-6","article-title":"Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models","volume":"74","author":"Pakola","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib54","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2023.04.001","article-title":"Simultaneous targeting of PD-1 and IL-2Rbetagamma with radiation therapy inhibits pancreatic cancer growth and metastasis","volume":"41","author":"Piper","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib55","article-title":"The role of interferon-gamma and its receptors in gastrointestinal cancers","volume":"248","author":"Mozooni","year":"2023","journal-title":"Pathol. Res. Pr."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.12.004_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1359-6101(01)00038-7","article-title":"The roles of IFN\u03b3 in protection against tumor development and cancer immunoediting","volume":"13","author":"Ikeda","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"7652","key":"10.1016\/j.cytogfr.2025.12.004_bib57","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature22311","article-title":"Tumour ischaemia by interferon-\u03b3 resembles physiological blood vessel regression","volume":"545","author":"Kammertoens","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.12.004_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/jir.2007.0025","article-title":"IFN-gamma induces apoptosis in HL-60 cells through decreased Bcl-2 and increased Bak expression","volume":"28","author":"Zhou","year":"2008","journal-title":"J. Interferon Cytokine Res"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.12.004_bib59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/jir.2018.0070","article-title":"Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2\/Rac1\/NF-\u03baB Signaling Pathway","volume":"38","author":"Zhang","year":"2018","journal-title":"J. Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.12.004_bib60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/1096-9098(200010)75:2<122::AID-JSO9>3.0.CO;2-4","article-title":"Direct growth suppressive activity of interferon-alpha and -gamma on human gastric cancer cells","volume":"75","author":"Shyu","year":"2000","journal-title":"J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.12.004_bib61","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.7314\/APJCP.2013.14.9.5513","article-title":"Anti-proliferation effects of interferon-gamma on gastric cancer cells","volume":"14","author":"Zhao","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.12.004_bib62","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1245\/s10434-011-1683-6","article-title":"Transcriptional factor Prox1 plays an essential role in the antiproliferative action of interferon-\u03b3 in esophageal cancer cells","volume":"18","author":"Akagami","year":"2011","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.12.004_bib63","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1593\/neo.06595","article-title":"Loss of Function of the Candidate Tumor Suppressor prox1 by RNA Mutation in Human Cancer Cells","volume":"8","author":"Takahashi","year":"2006","journal-title":"Neoplasia"},{"issue":"20","key":"10.1016\/j.cytogfr.2025.12.004_bib64","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1158\/1078-0432.CCR-06-0712","article-title":"A Homeobox Protein, Prox1, Is Involved in the Differentiation, Proliferation, and Prognosis in Hepatocellular Carcinoma","volume":"12","author":"Shimoda","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.12.004_bib65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2008.02.020","article-title":"Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype","volume":"13","author":"Petrova","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib66","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib67","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/path.5214","article-title":"Interferon-\u03b3 directly induces gastric epithelial cell death and is required for progression to metaplasia","volume":"247","author":"Osaki","year":"2019","journal-title":"J. Pathol."},{"issue":"27","key":"10.1016\/j.cytogfr.2025.12.004_bib68","doi-asserted-by":"crossref","first-page":"42099","DOI":"10.18632\/oncotarget.9867","article-title":"Lack of interferon-\u03b3 receptor results in a microenvironment favorable for intestinal tumorigenesis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.12.004_bib69","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1158\/0008-5472.CAN-10-4009","article-title":"IFN-\u03b3 Inhibits Gastric Carcinogenesis by Inducing Epithelial Cell Autophagy and T-Cell Apoptosis","volume":"71","author":"Tu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114526","article-title":"Metabolic reprogramming and interventions in endometrial carcinoma","volume":"161","author":"Li","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.12.004_bib71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/eos.12131","article-title":"Expression of CD163, interleukin-10, and interferon-gamma in oral squamous cell carcinoma: mutual relationships and prognostic implications","volume":"122","author":"Wang","year":"2014","journal-title":"Eur. J. Oral. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.12.004_bib72","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00784-017-2052-z","article-title":"Hypermethylation of IFN-\u03b3 in oral cancer tissues","volume":"21","author":"Tian","year":"2017","journal-title":"Clin. Oral. Invest."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.12.004_bib73","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib74","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1089\/jir.2018.0087","article-title":"The Interferon-Gamma Paradox in Cancer","volume":"39","author":"Zaidi","year":"2019","journal-title":"J. Interferon Cytokine Res"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.12.004_bib75","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.12.004_bib76","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual Faces of IFN\u03b3 in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbiotec.2016.10.022","article-title":"Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation","volume":"240","author":"Razaghi","year":"2016","journal-title":"J. Biotechnol."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib78","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1186\/s12885-019-6145-8","article-title":"IFN-\u03b3 down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer","volume":"19","author":"Ding","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cytogfr.2025.12.004_bib79","article-title":"Synergistic effect of IFN-\u03b3 and IL-1\u03b2 on PD-L1 expression in hepatocellular carcinoma","volume":"30","author":"Numata","year":"2022","journal-title":"Biochem Biophys. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.12.004_bib80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cytogfr.2025.12.004_bib81","doi-asserted-by":"crossref","first-page":"1056144","DOI":"10.3389\/fimmu.2022.1056144","article-title":"A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer","volume":"13","author":"Li","year":"2023","journal-title":"Front Immunol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:46:13Z","timestamp":1769604373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":81,"alternative-id":["S1359610125001625"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.12.004","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of anti-tumorigenic cytokines in gastrointestinal cancers","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}